Company Filing History:
Years Active: 1988-1992
Title: Michael Rosenblatt: Innovator in Peptide Analogues
Introduction
Michael Rosenblatt is a distinguished inventor based in Ardmore, PA (US). He has made significant contributions to the field of peptide analogues, holding a total of 7 patents. His work focuses on developing inhibitors for naturally occurring peptides, which has important implications in medical science.
Latest Patents
Rosenblatt's latest patents include innovations such as "Humoral hypercalcemic factor antagonists." This invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of these peptide analogues is exemplified by an internal region of the N-terminus of humoral hypercalcemic factor hHCF, along with various truncations and amino acid substitutions. Another notable patent is "Antagonists with position 13 modification," which involves the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormones. In this case, the structure is exemplified by parathyroid hormone (PTH), where Lys.sup.13 is substituted to enhance the biological activity of the PTH analogues.
Career Highlights
Rosenblatt has had a successful career at Merck & Co., Inc., where he has been instrumental in advancing research in peptide analogues. His innovative approaches have led to breakthroughs that are valuable in therapeutic applications.
Collaborations
Throughout his career, Rosenblatt has collaborated with notable colleagues, including Michael Chorev and Ruth F Nutt. These partnerships have fostered a collaborative environment that enhances the research and development of new inventions.
Conclusion
Michael Rosenblatt's contributions to the field of peptide analogues exemplify the impact of innovation in medical science. His patents and collaborations continue to influence the development of new therapeutic strategies.